您使用提示模式 关闭
为了方块之间的快速移动

组织机构: Vertex Pharmaceutical
LEI 54930015RAQRRZ5ZGJ91, Swift码 VRTXUS33XXX

机构名称
Vertex Pharmaceuticals Incorporated
国家名称
美国
注册登记国
美国
行业
药品生产和生物技术
债券负债
-

探索最全面的数据库

80 万

债券

超过 400

定价来源

8 万

股票

9 千

ETF

以最有效的方式跟踪您的投资组合
债券筛选器
观察列表
Excel 附加组件

最新数据在

卖价

查询已发送
无法访问
信息提供者所提供的报价仅供参考。

简介

Vertex Pharmaceuticals Incorporated (Vertex) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases. The Company’s two products are INCIVEK (telaprevir), which is approved for the treatment of patients with genotype 1 hepatitis C virus (HCV), infection, and KALYDECO (ivacaftor), which is approved in the United States for the treatment of patients six years of age and older with cystic fibrosis (CF), who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR), gene. The Company has ongoing clinical programs involving drug candidates intended for the treatment of HCV infection, CF, rheumatoid arthritis, influenza and epilepsy. / upd. 08. 2012

奖项

相关文件

股票

债券负债 (按货币)

代码

  • LEI
    54930015RAQRRZ5ZGJ91
  • Swift码
    VRTXUS33XXX
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • CIK
    0000875320
  • EIN
    04-3039129

信用和 ESG 评级

宏观经济指数

你必须 注册 才能获得访问权